RU2013105211A - APPLICATION OF TERAPEPTIDE Arg-Pro-Gly-Pro AS A MEANS FOR PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA, METHOD FOR PREVENTION AND TREATMENT OF HYPERCHOLESTEREMIA, PHARMACEUTICAL CHEMISTROSIS - Google Patents
APPLICATION OF TERAPEPTIDE Arg-Pro-Gly-Pro AS A MEANS FOR PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA, METHOD FOR PREVENTION AND TREATMENT OF HYPERCHOLESTEREMIA, PHARMACEUTICAL CHEMISTROSIS Download PDFInfo
- Publication number
- RU2013105211A RU2013105211A RU2013105211/15A RU2013105211A RU2013105211A RU 2013105211 A RU2013105211 A RU 2013105211A RU 2013105211/15 A RU2013105211/15 A RU 2013105211/15A RU 2013105211 A RU2013105211 A RU 2013105211A RU 2013105211 A RU2013105211 A RU 2013105211A
- Authority
- RU
- Russia
- Prior art keywords
- pro
- peptide
- prevention
- gly
- treatment
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Применение тетрапептида Arg-Pro-Gly-Pro в качестве средства профилактики и лечения гиперхолестеринемии.2. Способ профилактики и лечения гиперхолестеринемии, включающий интраназальное введение лекарственного средства на основе тетрапептида Arg-Pro-Gly-Pro в эффективном количестве.3. Фармацевтическая композиция для профилактики и лечения гиперхолестеринемии, включающая пептид с гипохолестеринемическим действием в качестве активного вещества и фармацевтически приемлемое вспомогательное вещество в качестве консерванта, отличающаяся тем, что в качестве пептида использован пептид общей формулы Arg-Pro-Gly-Pro или его фармацевтически приемлемая соль.4. Композиция по п.3, отличающаяся тем, что содержание пептида или его фармацевтически приемлемой соли составляет 0,1÷1,0 вес.%.5. Композиция по п. 3 или 4, отличающаяся тем, что она выполнена приемлемой для интраназального введения.6. Композиция по п.5, отличающаяся тем, что она выполнена в виде раствора следующего состава: пептид Arg-Pro-Gly-Pro или его фармацевтически приемлемая соль - 1÷10 г/л; нипагин - 0,9÷1,1 г/л в качестве консерванта, дистиллированная вода - до 1 л.7. Способ получения фармацевтической композиции для профилактики и лечения гиперхолестеринемии, включающий смешивание активного и вспомогательных веществ, отличающийся тем, что в качестве активного вещества используют пептид общей формулы Arg-Pro-Gly-Pro или его фармацевтически приемлемую соль.8. Способ по п.7, отличающийся тем, что содержание пептида или его фармацевтически приемлемой соли составляет 0,1÷1,0 вес.%.9. Способ по п.7 или 8, отличающийся тем, что композицию получают в форме, приемлемой для интраназального введения.10. Способ по п.9, о1. The use of the tetrapeptide Arg-Pro-Gly-Pro as a means of prevention and treatment of hypercholesterolemia. 2. A method for the prevention and treatment of hypercholesterolemia, including the intranasal administration of a drug based on the tetrapeptide Arg-Pro-Gly-Pro in an effective amount. 3. A pharmaceutical composition for the prevention and treatment of hypercholesterolemia, including a peptide with hypocholesterolemic action as an active substance and a pharmaceutically acceptable excipient as a preservative, characterized in that the peptide used is a peptide of the general formula Arg-Pro-Gly-Pro or its pharmaceutically acceptable salt. four. The composition according to claim 3, characterized in that the content of the peptide or its pharmaceutically acceptable salt is 0.1 ÷ 1.0 wt.%. 5. A composition according to claim 3 or 4, characterized in that it is made acceptable for intranasal administration. The composition according to claim 5, characterized in that it is made in the form of a solution of the following composition: Arg-Pro-Gly-Pro peptide or its pharmaceutically acceptable salt - 1 ÷ 10 g / l; nipagin - 0.9 ÷ 1.1 g / l as a preservative, distilled water - up to 1 l. 7. A method of obtaining a pharmaceutical composition for the prevention and treatment of hypercholesterolemia, comprising mixing the active and auxiliary substances, characterized in that the active substance is a peptide of the general formula Arg-Pro-Gly-Pro or a pharmaceutically acceptable salt thereof. The method according to claim 7, characterized in that the content of the peptide or its pharmaceutically acceptable salt is 0.1 ÷ 1.0 wt.%. 9. The method according to claim 7 or 8, characterized in that the composition is obtained in a form acceptable for intranasal administration. The method according to claim 9, about
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013105211/15A RU2538801C2 (en) | 2013-02-07 | 2013-02-07 | USING TETRAPEPTIDE Arg-Pro-Gly-Pro AS AGENT FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, METHOD FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA AND METHOD FOR PREPARING IT |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013105211/15A RU2538801C2 (en) | 2013-02-07 | 2013-02-07 | USING TETRAPEPTIDE Arg-Pro-Gly-Pro AS AGENT FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, METHOD FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA AND METHOD FOR PREPARING IT |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2013105211A true RU2013105211A (en) | 2014-08-20 |
RU2538801C2 RU2538801C2 (en) | 2015-01-10 |
Family
ID=51384075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013105211/15A RU2538801C2 (en) | 2013-02-07 | 2013-02-07 | USING TETRAPEPTIDE Arg-Pro-Gly-Pro AS AGENT FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, METHOD FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA AND METHOD FOR PREPARING IT |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2538801C2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR087305A1 (en) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT |
CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2403909C1 (en) * | 2009-10-23 | 2010-11-20 | Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) | Method of treating diabetes in mammals and intranasal pharmaceutical composition for treating diabetes in mammals |
-
2013
- 2013-02-07 RU RU2013105211/15A patent/RU2538801C2/en active
Also Published As
Publication number | Publication date |
---|---|
RU2538801C2 (en) | 2015-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690287A1 (en) | 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY | |
MX2021006421A (en) | Amino-acid anilides as small molecule modulators of il-17. | |
WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
RU2014149181A (en) | PYRAZOLE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES | |
EA201290860A1 (en) | TREATMENT OF RHEUMATOID ARTHRITIS BY COMBINATION OF LAKVINIMODA AND METHOREXAT | |
PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
RU2017118971A (en) | Amino Acid Composition for Restoring Fibroelastin in Dermal Connective Tissues | |
EA201691490A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING BRINZOLAMIDE | |
EA201590193A1 (en) | LAKVINIMODA PREPARATIONS WITHOUT AN AGENT AGENT | |
EA201790223A1 (en) | WATER PREPARATION CONTAINING PARACETAMOL AND IBUPROFEN | |
RU2016112257A (en) | COMPOSITION FOR THE TREATMENT OF HYPERTENSION AND / OR FIBROSIS | |
EA201390950A1 (en) | HOMOGENEOUS PHARMACEUTICAL ORAL DOSAGE FORMS CONTAINING LERKANIDIPIN AND ENALAPRIL OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS TOGETHER WITH ORGANIC ACID | |
EA201991490A1 (en) | AROMATIC AMIDES OF CARBOXYLIC ACIDS AS BRAKININ B1 RECEPTOR ANTAGONISTS | |
RU2013105211A (en) | APPLICATION OF TERAPEPTIDE Arg-Pro-Gly-Pro AS A MEANS FOR PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA, METHOD FOR PREVENTION AND TREATMENT OF HYPERCHOLESTEREMIA, PHARMACEUTICAL CHEMISTROSIS | |
EA201591418A1 (en) | MULTICOMPONENT CRYSTAL PARTICLES FOR INHALATION THERAPY | |
RU2014130894A (en) | PEPTID POSSESSING NEUROPROTECTOR AND NOTROPIC ACTIVITY, AND PHARMACEUTICAL COMPOSITION ON ITS BASIS | |
EA201592297A1 (en) | AGOMELATIN COMPOSITIONS CONTAINING AGOMELATIN IN THE FORM OF CRYSTALS | |
EA201400484A1 (en) | TRANSDERMAL MEANS FOR THE TREATMENT AND PREVENTION OF DISEASES OF JOINT AND SOFT TISSUES | |
BR112015015938A2 (en) | use of phenylephrine and acetaminophen hydrochloride, drug, method of treatment of upper respiratory tract mucosal congestion in an adult human | |
RU2012135798A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SKIN ITCH | |
RU2019102890A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING FLURBIPROPHEN | |
RU2013105212A (en) | APPLICATION OF PRO-Gly-Pro-Val TETREPEPTIDE AS A MEANS FOR PREVENTION AND TREATMENT OF LIPID METABOLISM DISORDERS, METHOD OF PREVENTION AND TREATMENT OF LIPID METABOLISM VIOLATIONS, PHARMACEUTICAL COMPOSITION | |
AR074470A1 (en) | AMIDA COMPOUND OF THE CYCLOPROPANOCARBOXYL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES | |
RU2014148062A (en) | INJECTION PHARMACEUTICAL COMPOSITION OF DEXKETOPROFEN AND TRAMADOL | |
MX362435B (en) | Novel pharmaceutical system of biphasic delivery for treating pain and inflammation. |